This drug manufacturer has seen three positive and two negative estimate revisions over the last 30 days whiled its Zacks Consensus Estimate remained same over the same time frame, suggesting that more solid trading could be ahead for BioCryst Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent move higher can turn into more strength down the road.
BioCryst Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked stocks in the same industry include Biomerica Inc. (BMRA), Cardiome Pharma Corp. (CRME) and POZEN Inc. (POZN). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment